These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32666268)

  • 1. Roxadustat (FG-4592) accelerates pulmonary growth, development, and function in a compensatory lung growth model.
    Ko VH; Yu LJ; Dao DT; Li X; Secor JD; Anez-Bustillos L; Cho BS; Pan A; Mitchell PD; Kishikawa H; Puder M
    Angiogenesis; 2020 Nov; 23(4):637-649. PubMed ID: 32666268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency in pigment epithelium-derived factor accelerates pulmonary growth and development in a compensatory lung growth model.
    Ko VH; Yu LJ; Secor JD; Pan A; Mitchell PD; Kishikawa H; Puder M
    FASEB J; 2021 Oct; 35(10):e21850. PubMed ID: 34569654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor accelerates compensatory lung growth by increasing the alveolar units.
    Dao DT; Nandivada P; Vuong JT; Anez-Bustillos L; Pan A; Kishikawa H; Mitchell PD; Baker MA; Fell GL; Martin T; Puder M
    Pediatr Res; 2018 Jun; 83(6):1182-1189. PubMed ID: 29638228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain.
    Yu LJ; Ko VH; Dao DT; Secor JD; Pan A; Cho BS; Mitchell PD; Kishikawa H; Bielenberg DR; Puder M
    Sci Rep; 2021 Jun; 11(1):11827. PubMed ID: 34088930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor.
    Dao DT; Anez-Bustillos L; Jabbouri SS; Pan A; Kishikawa H; Mitchell PD; Fell GL; Baker MA; Watnick RS; Chen H; Rogers MS; Bielenberg DR; Puder M
    PLoS One; 2018; 13(12):e0208579. PubMed ID: 30566445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxadustat promotes angiogenesis through HIF-1α/VEGF/VEGFR2 signaling and accelerates cutaneous wound healing in diabetic rats.
    Zhu Y; Wang Y; Jia Y; Xu J; Chai Y
    Wound Repair Regen; 2019 Jul; 27(4):324-334. PubMed ID: 30817065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.
    Dao DT; Anez-Bustillos L; Ourieff J; Pan A; Mitchell PD; Kishikawa H; Fell GL; Baker MA; Watnick RS; Chen H; Hamilton TE; Rogers MS; Bielenberg DR; Puder M
    Angiogenesis; 2018 Nov; 21(4):837-848. PubMed ID: 29956017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
    Zhu L; Xie J; Liu Z; Huang Z; Huang M; Yin H; Qi W; Yang Z; Zhou T; Gao G; Zhang J; Yang X
    Cancer Sci; 2018 Jun; 109(6):1981-1994. PubMed ID: 29664206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of systemic anticoagulation in a murine model of compensatory lung growth.
    Yu LJ; Ko VH; Tsikis ST; Dao DT; Secor JD; Pan A; Cho BS; Michell PD; Fligor SC; Kishikawa H; Puder M
    Pediatr Res; 2023 Jun; 93(7):1846-1855. PubMed ID: 36195630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
    Zhang SX; Wang JJ; Gao G; Parke K; Ma JX
    J Mol Endocrinol; 2006 Aug; 37(1):1-12. PubMed ID: 16901919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H; Wang X; Zhang X; Wang H; Jiang W
    Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vascular endothelial growth factor receptor-1 signaling in compensatory contralateral lung growth following unilateral pneumonectomy.
    Matsui Y; Amano H; Ito Y; Eshima K; Tamaki H; Ogawa F; Iyoda A; Shibuya M; Kumagai Y; Satoh Y; Majima M
    Lab Invest; 2015 May; 95(5):456-68. PubMed ID: 25642830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy.
    Sakurai MK; Lee S; Arsenault DA; Nose V; Wilson JM; Heymach JV; Puder M
    Am J Physiol Lung Cell Mol Physiol; 2007 Mar; 292(3):L742-7. PubMed ID: 17122356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT; Lo YC; Gao ZH; Wu SN
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
    Nishide S; Uchida J; Matsunaga S; Tokudome K; Yamaguchi T; Kabei K; Moriya T; Miura K; Nakatani T; Tomita S
    J Pharmacol Sci; 2020 Jun; 143(2):122-126. PubMed ID: 32199747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEDF is an endogenous inhibitor of VEGF-R2 angiogenesis signaling in endothelial cells.
    Zhang M; Tombran-Tink J; Yang S; Zhang X; Li X; Barnstable CJ
    Exp Eye Res; 2021 Dec; 213():108828. PubMed ID: 34742690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells.
    Sheikpranbabu S; Ravinarayanan H; Elayappan B; Jongsun P; Gurunathan S
    Vascul Pharmacol; 2010; 52(1-2):84-94. PubMed ID: 20006737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.